

INTRODUCTION 220718au3

Drugs Against Cancer: Stories of Discovery and the Quest for a Cure

Kurt W. Kohn, MD, PhD
Scientist Emeritus
Laboratory of Molecular Pharmacology
Developmental Therapeutics Branch
National Cancer Institute
Bethesda, Maryland
kohnk@nih.gov

INTRODUCTION

I should perhaps begin by relating how it happened that I was to devote nearly 60 years of my life to anti-cancer drug research at the National Cancer Institute (NCI) in Bethesda, Maryland. In his recent book, "The Death of Cancer, 2015" (DeVita Jr., 2015), Vincent DeVita writes of his early life, which in some ways parallels my own. We both grew up in New York in the 1940's, although he was a few years younger, and we did not know each other. We attended different medical schools, and independently joined the United States Public Health Service as an alternative to becoming inducted as young doctors in the armed forces of the United States. We both became Clinical Associates (physicians in training) at the National Cancer Institute, which, for both of us was a second choice. DeVita's first choice would have been the Heart Institute, while I had at first aimed for a research position in a neurophysiology group. He relates his early formative experience at the age of 6 when a beloved aunt died of disseminated cancer. Mine would have been our family's narrow escape from Nazi Vienna in August 1938, when I was 7 years old.

DeVita then spent his career developing cancer cures in clinical research, whereas my bent was for laboratory research to try to find out how anti-cancer drugs work. Upon arriving at NCI in 1957, I was assigned to a Clinical Pharmacology unit and thought it a promising direction to take in view of my interest in chemistry, in which I had majored at Harvard College (chemistry and physics combined major). My first assignment however was to help care for children on the acute leukemia service, after which I was assigned to the adult cancer ward. That occupied much of my first two years at NCI.

In his book, DeVita tells of a pretty 10 year old girl with acute leukemia to whose room he was called one night, while he was an intern at the University of Michigan in 1962 (DeVita Jr., 2015). She was in the last stage of her disease and he was called upon to restart an I.V. that had stopped working. Her overused veins were difficult to access, but he was lucky and slipped the needle into a vein on the first try. She

smiled, because it was long since a needle had not hurt ... and she gave him a 50-cent coin in appreciation. He says that it was this image that he took with him when he came to work in the childhood leukemia ward at NCI.

When I was a third-year medical student I saw a very intelligent young man of about 20 who was in the last stage (blast crisis) of acute leukemia, and for whom nothing more could be done at the time. I saw him vomiting blood continuously . . . but he kept apologizing to the nurses for making such a mess! That poignant image was with me when I arrived to work in the same childhood leukemia ward in 1957 -- 2 East on the second floor of the Clinical Center -- a few years earlier than DeVita.

I was recruited to the Clinical Associate program of NCI's new clinical research program by NCI Clinical Director C. Gordon Zubrod (Figure 0.5), who recognized my bent and background in physical sciences and wisely assigned me to work with David P. Rall (Figure 0.6) in the new Clinical Pharmacology Service in NCI's Medicine Branch to begin after my first 2 years in the childhood leukemia and adult cancer clinical programs.

The childhood leukemia ward in 1957 had some of the same feel to it that DeVita describes when he was a Clinical Associate there about 5 years later. Though depressing to those who knew the score, the nurses managed to keep everyone who was not in immediate pain cheerful. Although some of the children would go into brief remission, all them soon died. Nevertheless, we all suppressed the dreadful facts as we watched cheerful television cartoons with the children on sunny weekend mornings. The designers of the Clinical Center were wise to place the patient wards on the South side of the building.

In order to avoid being drafted, I did not go on to residency training and came directly to NCI right after internship. Therefore, I was really under-qualified for my role to help care for very sick children. But fortunately, I had excellent guidance and supervision from Emil J Freireich ("Jay"), who was chief of the unit.

In our regular meetings with Emil Frei ("Tom"), who headed the entire NCI clinical program, we reviewed the drug treatments and clinical problems and continued our discussions at breakfast in the cafeteria. Tom always had a stack of big yellow punched cards (the best data management system at the time) sticking out of a pocket of his long white coat. I asked many questions, and was impressed by his scholarly answers, which he always backed up with specific data references.

J Freireich was full of wild ideas that he expressed with great confidence, in contrast to Tom Frei's scholarly precision. But both were intent on getting an effective drug treatment for leukemia. Their different ways of thinking complemented each other, and their collaboration was extraordinarily productive. Any idea of a cure however was far away in the fog. The personalities and extraordinary successes of the Freireich-Frei duo is well described by John Laszlo in his book "The Cure of Childhood Leukemia" (Laszlo, 1995). Freireich's delight with any new idea that

might come to mind and Frei's scholarly demeanor, are well shown in old photos I found on the internet (Figure 0.4). Frei's scholarly demeanor, by the way, hid a brilliant sense of humor and a talent for vaudeville accentuated by his height and long legs.

In 1957, we were giving only one drug at a time, methotrexate or 6-mercaptopurine. Since two or more antibiotics given together were known to help patients with tuberculosis, I naively suggested in our meetings with Tom Frei that we try giving both drugs together. That idea was promptly shot down, because we didn't yet know enough about the actions of each of those drugs by itself.

DeVita describes the triumvirate: Freireich, Frei and Rall, and their single-minded efforts to cure cancer, particularly leukemia. He well described Freireich and Frei, and how their eccentric personalities helped to eventually get a cure. My wife, Elaine, and I attended many parties at the Rall's and Frei's and were entertained by Tom's Vaudeville talents, although we missed the wild party described by DeVita (DeVita Jr., 2015).

After my stint in the childhood leukemia and adult cancer wards, I joined David Rall (Figure 0.6) in his studies of how drugs could be made to pass the blood-brain barrier. Like DeVita, I had been recruited by Rall for the Clinical Associate position. The blood-brain barrier was one of the road-blocks to effective treatment, because it kept the drugs out of the brain where residual leukemia cells were often lurking.

In those early days, I did not have much hope for the trial-and-error clinical drug testing, and felt it was better to take the basic science tack. Therefore, I stuck to the lab and gradually reduced my attendance at ward rounds.

The first 4-drug combination, VAMP, seemed bizarre . . . but it produced a few cures (DeVita Jr., 2015). I couldn't have been more surprised! It had seemed to me that the drug combination was designed empirically without sufficient basic knowledge. I was mistaken, however, because the combination design was based on careful dosage and toxicity considerations, as well as some general notions of drug mechanisms. The combination worked, even though our knowledge of how it worked was mostly lacking.

I was greatly encouraged and inspired by close association with members of the Clinical Pharmacology Service to which I had been assigned: Dave Rall, Ti Li Loo, Jack Davidson and we would often continue our discussions at lunch in the cafeteria in the B1 level of the Clinical Center. The labs of the Clinical Pharmacology Service, by the way, were located in the East wing on the 6th floor of the Clinical Center.

Dave Rall (Figure 0.6) had wonderful insights in physiology, particularly about the anatomy and physiology of the blood-brain barrier and the chemical factors (ionization states) of drugs that determine their ability to penetrate the barrier and enter the brain.

Ti Li Loo (Figure 07) was an organic and medicinal chemist with whom I had many fruitful discussions about chemical mechanisms and how the different ionization states of compounds can be determined by spectral analysis.

Jack D. Davidson had keen physical insight and liked to design and modify experimental apparatus. He was a leader in the field of scintillation counting of radioactivity in biological samples and had one the first automatic multi-sample scintillation counters manufactured. He solved the problem of how to dissolve an aqueous biological sample in the toluene-based solution required to produce the scintillations. His reading and commenting on my first manuscripts before submission for publication were extremely helpful. He went on to head the Nuclear Medicine department in the NIH Clinical Center.

My first research in the Clinical Pharmacology Service of the Medicine Branch (1957-1959) followed up on a clever (albeit unsuccessful) attempt to discover a new anti-cancer vitamin analog. One of the senior scientists in our group, Montague ("Monty") Lane, was engaged in a project that caught my attention. Since methotrexate, an analog of folic acid, was successful as an anti-cancer drug, Monty decided to test an analog of another vitamin, riboflavin. In animal tests, Monty had assured himself that his riboflavin analog was not toxic. He then tried the riboflavin analog on one of his patients whose cancer was very advanced and terminal, and for whom no further therapy was known. (In 1956, constraints on clinical testing were not yet formalized.) When the patient soon died of her disease, Monty wanted to look for the strong fluorescence of riboflavin to see whether it had gotten into her tumors. He indeed saw bright fluorescence in the cancer tissues. But he found that the fluorescence in the tumor was not due to his riboflavin analog. Checking the clinical record, he found that the patient had been given tetracycline to treat an infection. He found that the bright fluoresce indeed was due to tetracycline that was concentrated in the tumor tissue.

That piqued my interest, and my first research projects at NIH focused on tetracycline as an agent that selectively bound to tumor tissue (Kohn, 1961a, b). It later turned out, however, that tetracycline was binding only in the necrotic (i.e., dead) parts of the cancer tissue. So, that idea led to a dead end as far as therapy was concerned.

Dave Rall, however, was interested in my work for another reason: it seemed a good way to investigate how a drug passed through the blood-brain barrier. I had found that, when tetracycline binds calcium, it can be induced to migrate into a lipid solvent (analogous to the lipid layer that constitutes the blood-brain barrier), where its fluorescence in the lipid phase was greatly enhanced, which made it easy to detect and measure by means of an assay I had developed (Kohn, 1961a). (That first paper of mine, by the way, was published in *Analytical Chemistry*, which was ironic, because I had managed to avoid courses on that seemingly uninteresting area of chemistry at college.)

In order to induce the tetracycline-calcium complex to become highly lipid-soluble, however, a third component was necessary – the most effective turned out to be a barbiturate. In order to test various barbiturates, I was able to order them from chemical companies, because access to many drugs that were to become widespread abuse problems was not yet restricted. Years later, I discovered in the back of a high shelf a dusty old brown bottle that contained nearly half a pound of pentobarbital that I had recrystallized and later forgotten, and I had to explain why I had in my possession a large quantity of a restricted drug without proper approval and documentation.

Anyway, I applied those findings to devise a new sensitive assay for tetracycline, which we used to investigate the permeation of tetracycline from the blood into the brain. I also found that calcium mediates the binding tetracycline to DNA (Kohn, 1961b). Those were my first studies at NIH, before I moved to work in Paul Doty's laboratory at Harvard for two years.

When DeVita was Director of the Division of Cancer Treatment at NCI, I was Chief of the Laboratory of Molecular Pharmacology that I had founded in the Division. In our discussions and conferences, we sometimes disagreed, but he listened carefully to alternative views and was always cordial. He had the difficult task of encouraging creative research while keeping on track to curing cancer. It was a difficult task, where one could never be sure that his/her decision was the best one. His viewpoint was well expressed at a Division meeting when a major new effort was being debated. When I brought up why I thought that the planned project was unlikely to succeed, his response was a quote he attributed to Winston Churchill to the effect that "the demand for perfection spells paralysis."

In 1981, my Laboratory was joined by Yves Pommier who had received an MD degree from the University of Paris and carried out chemotherapy studies there. He became active in our studies of the effects of anti-cancer drugs on the DNA-associated enzyme topoisomerase II. We carried out much of the early work together and remained close colleagues and friends. His investigations progressed and expanded, leading to his appointment in 1995 to succeed me as Chief of the Laboratory of Molecular Pharmacology upon my retirement from that position. He later became Director of a new Developmental Therapeutics Branch that included the Laboratory as well a clinical research component. I tell about many of those investigations in the chapters that follow, including his role in the more recent drug discovery accomplishments at NCI.

Going back, my interest in science began around age 12 with a passion for astronomy, which led to my becoming active in the Junior Astronomy Club at the American Museum of Natural History in New York, among other teenagers who were passionate about mathematics and science; several of whom went on to become well known in those fields. Four of us came to Washington, DC as winners in the Westinghouse Science Talent Search of 1947, where we met other like-minded

young people; several of us then attended Harvard College and continued our friendship there. I wanted to become a physicist, but soon found that several of my friends had much more math talent than I did. Therefore, I thought to settle for physical chemistry. But I came to feel that the future was in biology, in which I also had an intense interest (my Science Talent Search project was on how ants recognize members of their nest mates). I guess I was driven by a desire to know how the physical and biological world worked as revealed by the sciences. Finally, I settled on the new field of biophysics, but was advised that in order to get into that field I should go to medical school, because that was where the best research was being done. I became enthusiastic about that idea, because I wanted to find out how the human body and medical treatments work. And so it happened that my father's urging me to go to medical school came to fruition after all, whereas I had always denied any intention of doing that because I had thought it a diversion from pure science.

I attended Columbia's medical school, the College of Physicians and Surgeons (P&S) in New York. I had been set to attend Harvard Medical School but could not give up a New York State Medical Scholarship. However, P&S turned out to become a key to my future research, as I will go on to explain.

My professional life and experiences at P&S were in several ways entangled with some of the stories I tell in this book. That entanglement began in 1953 in Alfred Gilman's pharmacology lectures during my first year as a medical student at P&S. Gilman's lectures, although masterly in clarity and scope, were a challenge in note taking, because his crystal-clear delivery was rapid and unrelenting, and there were no practical recording devices, no internet, and the only informative pharmacology textbook, the first edition of Goodman and Gilman's classic, "The Pharmacological Basis of Therapeutics" (1941), was hopelessly out of date.

As already mentioned, I had entered medical school after majoring in chemistry and physics, with the idea of preparing for research in some area of biophysics. For me, Gilman's key lecture turned out to be his description of the chemistry of nitrogen mustard, which he had a major role in elucidating during World War II (Gilman and Philips, 1946) (see Chapter 1). My ears perked up even more than usual in his always insightful lectures when he described how the nitrogen mustard molecule had to have *two* reactive sites in order to be effective as an anti-cancer drug. Moreover, the chemistry Gilman had helped to unravel showed that the two sites could each bind tightly (covalently) to something. Evidently nitrogen mustard worked by forming tight cross-links in or between some important biomolecules; but what were they? That question intrigued me but remained latent in my mind until aroused unexpectedly 7 years later.

I may have already associated the number *two* from Gilman's lecture with the number of strands in Watson and Crick's 1953 model of DNA. Those two strands have to separate in order to form new copies of the genetic material before the cell divides. If some tight crosslink held them together, the DNA could not be duplicated,

and the cell could not divide normally. I'm not sure whether that notion was already hazily in my mind at the time, but it became loud and clear when I started working in Paul Doty's laboratory at Harvard as a post-doc in 1959 (see Chapter 1).

While at medical school, there was another connection with nitrogen mustard. My closest classmate friend, with whom I did my first research projects, was Edgar Haber (1932-1997) – we worked together on projects ranging from electronics to physiology and pharmacology – went on to an illustrious clinical and research career in cardiology. Ed was a relative of Fritz Haber, the inventor of mustard gas. Chapter 1 relates the story of how that World War I poison gas was a prelude to the development of nitrogen mustard as the first anti-cancer drug. I will also touch upon the ethical issues of Fritz Haber's poison gas research (see Chapter 1). I will also note that Fritz Haber's development of the process to produce ammonia from atmospheric nitrogen, so as to provide a desperately needed new source for agricultural fertilizer saved more lives from starvation than were lost during both World Wars combined. Benefit-harm dualities, however, are often complicated: the Haber-Bosch process for converting atmospheric nitrogen to ammonia and hence nitrates, also fueled Germany's production of explosives for weaponry and may have prolonged the war.

In the meantime, I had graduated from medical school, interned at Mount Sinai Hospital in New York, joined the U.S. Public Health Service as a medical officer, and gotten a job as a Clinical Associate at the National Cancer Institute in Bethesda, Maryland. Also in the meantime, I had married Elaine Kay Mogels (1931-2013) and we soon had two children, Philip and Julia. During our first year in Bethesda, Elaine and I both had jobs in the new NIH Clinical Center. Living and working in Bethesda in 1957 was wonderful, especially for us New York city dwellers. It was a very pleasant rustic rural setting in which the NIH was mostly manicured lawns, trees, shrubs and flowers. The new Clinical Center stood out as a huge all-brick monument (Figure 0.1).

But my entanglement with the events to be related also had a clinical and biological side, which has to do with how it happened that I came to do research at the then little-known National Institutes of Health (NIH). During my 3rd medical school year (1955), I had a 3-month elective at Goldwater Memorial Hospital on Welfare Island (now known as Roosevelt Island) in New York's East River (Figure 0.2). It was a chronic disease hospital where Columbia had two clinical research units; I was assigned to a unit of all-male patients that was studying hypertension; the other was an all-female unit focused on rheumatoid arthritis. During my time at Goldwater, we had a guest lecturer from the NIH, Sidney Udenfriend (1918-1999), who had worked on the anti-malarial drug discovery program at Goldwater during the World War II. He was one of the many researchers from Goldwater who were recruited to staff the expanding NIH. Indeed, I heard the NIH referred to as "the Goldwater on the Potomac"! For me, however, it spelled an opportunity for a research career. Moreover, Udenfriend's lecture influenced my initial research direction at NIH. He described his use of the new spectrophotofluorometer he had developed together

with Robert Bowman and that was manufactured by AMINCO (Udenfriend, 1995) (Figure 0.3). It became the major research instrument in my tetracycline studies (Kohn, 1961b). It was a strange feeling recently to see that instrument in the museum exhibits in the Clinical Center. It was also a strange feeling to see the analytical ultracentrifuge, which was the major research instrument in my DNA crosslinking studies (Kohn et al., 1966), also consigned to “ancient history” museum displays (see Chapter 1). In both cases, I witnessed the origin and finite lifespan of a new research technology.

The present work summarizes some of the main stories behind the discoveries, successes and failures in the early efforts to develop drug treatments for cancer. Tremendous advances have been made in recent decades and the outlook for the future is bright. However, the early history that contributed to those recent advances is not so well known. I focus on past discoveries with the view that the era of cytotoxic cancer chemotherapy may gradually wane as molecularly targeted therapies come to the fore. It may be appropriate therefore for some of us who have experienced that early period, to assemble the highlights of how those discoveries were made and how they progressed to the current era of research and clinical application.

Chapters 1 through 13 relate the history of discovery and mechanisms of action of each of the major cancer chemotherapy drugs. The subsequent chapters relate the advent of targeted cancer therapeutic agents, such as inhibitors and monoclonal antibodies directed against tyrosine kinase enzymes and molecules required to repair damaged DNA. They also focus on the interaction networks that determine life or death of a cell in response to anticancer treatment.




Figure 0.1. The National Institutes of Health (NIH) in 1955, shortly after completion of the Clinical Center (NIH Building 10, upper right), about 2 years before I started working there as a Clinical Associate in the National Cancer Institute. The Clinical Center was by far the largest building on campus (it was said to be one of the largest all-brick buildings in the world) and was to become even much larger with modern additions to right side (the North side) of the building. From the beginning, the Clinical Center included a hospital and research laboratories for several of the NIH Institutes. The meadow in the upper left was later replaced by new buildings. The building with pillars, near the center of the picture, is Building 1, which was the administrative center of NIH. All of the buildings in the foreground that are similar in architecture still existed in 2016, albeit with remodeled interiors. The rectangular building at the left edge of the picture, building 13, was the first major addition after the Clinical Center; it included mechanical shops for construction of new apparatus and an area for surplus equipment. The building visible through the trees at the top is the old Suburban Hospital across Old Georgetown Road from NIH.



Figure 0.2. Goldwater Memorial Hospital in 1938, as seen from the Queensborough Bridge. This vast chronic disease hospital was located on Welfare Island (later called Roosevelt Island), a two-mile sliver of land in the East River nestled between the Upper East Side and Astoria. In addition to caring for a large number of chronic disease patients, Goldwater included clinical research departments associated with the Columbia, Cornell, and NYU medical schools. The hospital, opened in 1939, was an immense facility designed to be a new model of medical care for patients with chronic illnesses. Researchers in the Columbia unit solved the anti-malaria drug problem during World War II. Many of those researchers were recruited to lead the clinical and research programs of the newly expanded NIH. The hospital closed in December 2013, but before its destruction, a detailed photographic record was made (<http://urbanomnibus.net/2014/04/autopsy-of-a-hospital-a-photographic-record-of-coler-goldwater-on-roosevelt-island/>).




Figure 0.3. Sidney Udenfriend (1918-2000) in the late 1950's. Resting on the tabletop in the background is an AMINCO-Bowman spectrophotofluorometer that he helped to develop, and that I used in my first studies at NIH, (Udenfriend, 1995).




Figure 0.4. Emil J Freireich (1927-2021) (left) and Emil "Tom" Frei III (1924-2013) (right) as I remember them in 1958; they taught me the essentials of clinical cancer chemotherapy research. After enduring family hardships in Chicago during the Great Depression, Freireich attended the University of Illinois and received an M.D. degree in 1949. After post-doctoral work in hematology, he joined the U.S. Public Health Service and came to the NIH in 1955. Emil ("Tom") Frei received his medical degree from Yale University in 1948, served in the Korean War and came to NCI in 1955. Frei and Freireich worked together to help develop the first combination chemotherapy for the cure of acute lymphoblastic leukemia in children. 1965 they

both moved to the M. D. Anderson Cancer Center in Huston, Texas, and continued their work there. In 1972, Frei moved to Boston to become physician-in-chief at the Dana-Farber Cancer Institute of Harvard University.



Figure 0.5. C. Gordon Zubrod (1914-1999) was clinical and research director of the National Cancer Institute (NCI) from 1956 until 1974, when he moved to direct the oncology program at the University of Miami Medical School and the Florida Comprehensive Cancer Center. He received an MD degree at Columbia College of Physicians and Surgeons in 1940. During World War II, he worked at Goldwater Memorial Hospital to find a replacement for quinine for the treatment of malaria. The sources of quinine had been cut off during the war. That work resulted in the development of chloroquine as a substitute for quinine.



Figure 0.6. David P. Rall (1926-1999) as I remember him in the 1960's. After an MS degree in Pharmacology, he went on to receive MD and PhD degrees from Northwestern University Medical School in 1951. He interned at Bellevue Hospital

in New York and then joined the National Cancer Institute in 1954 as a Medical Officer in the U. S. Public Health Service. At NCI, he was a Senior Scientist and later Chief of the Clinical Pharmacology Service, which later became the Laboratory of Chemical Pharmacology. His early studies of the blood-brain barrier were carried out together with Gordon Zubrod and aimed to eliminate leukemia cells lurking in the brain which most anticancer drugs could not penetrate into. Their experimental animal was the dogfish shark whose brain anatomy suited those studies, which they carried out in Maine and Bimini. He had prominent roles in investigations of the toxicity of anticancer drugs and on the screening of large numbers of compounds for anticancer activity. In 1971, he left the NCI and became Director of a new National Institute of Environmental Health Sciences (NIEHS) in North Carolina. He had prominent roles in governmental and international policy on environmental carcinogens until 1999, when he died as the result of a car accident in France. In his memory, the main NIEHS building was named after him.



Figure 0.7. Ti Li Loo (1918-2007) completed his undergraduate studies in China and then in 1943 began his studies of chemistry and pharmacology at Oxford University. After post-doctoral work at the University of Maryland and acquiring United States citizenship, he was recruited by Gordon Zubrod to the NCI in 1955 and was assigned to the Clinical Pharmacology Service, where I learned much from him. In 1965, he moved to the M. D. Anderson Cancer Center and continued his research activities there ([Loo Ti Li Oral History 1998](#)).

References

- DeVita Jr., V.T. (2015). *The Death of Cancer* (New York: Farrar, Straus and Giroux).
- Gilman, A., and Philips, F.S. (1946). The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. *Science* *103*, 409-415.
- Kohn, K.W. (1961a). Determination of tetracyclines by extraction of fluorescent complexes. *Anal Chem* *33*, 862-866.
- Kohn, K.W. (1961b). Mediation of divalent metal ions in the binding of tetracycline to macromolecules. *Nature* *191*, 1156-1158.

- Kohn, K.W., Spears, C.L., and Doty, P. (1966). Inter-strand crosslinking of DNA by nitrogen mustard. *Journal of molecular biology* *19*, 266-288.
- Laszlo, J. (1995). *The Cure of Childhood Leukemia: into the Age of Miracles*. (New Brunswick, New Jersey, USA: Rutgers University Press).
- Udenfriend, S. (1995). Development of the spectrophotofluorometer and its commercialization. *Protein Sci* *4*, 542-551.